Accudynamics Acquired by Halma
News Mar 07, 2011
Accudynamics, Inc., a precision manufacturer of components for medical and diagnostic equipment, has been acquired by UK-based Halma p.l.c., a leading safety, health and sensor technology group. Accudynamics will become part of Halma’s global group of fluid technology businesses.
Accudynamics has over 25 years' experience developing and manufacturing instrument components in its production facility. Its precision machined components, integrated electromechanical assemblies, and subassemblies are used by medical and diagnostic equipment manufacturers across the United States, Europe and Japan.
“Accudynamics will become the capstone company for the fluid technology group, offering complete assemblies that incorporate components made by our other companies,” explains Halma’s Fluid Technology Divisional Chief Executive, Chuck Dubois. “I expect extensive collaboration in both approaches to customers as well as new product development.”
Halma’s 36 worldwide subsidiaries focus on industrial safety, health and analysis and infrastructure sensors. Halma typically acquires companies in familiar markets or closely allied sectors. Accudynamics will fit into the fluid technology sector of Halma’s health and analysis business group.
The companies in this group, Alicat Scientific, Bio-Chem Fluidics, Diba Industries and Perma Pure manufacture critical components used by scientific, environmental and medical diagnostic instrument manufacturers for demanding fluid handling applications. Accudynamics already works closely with Diba, incorporating many of Diba’s components into its assemblies.
Commenting on the acquisition, Accudynamics founder and President George Ballou said, “Our successful track record, coupled with the resources of Halma p.l.c., will be a winning combination for the future growth of Accudynamics. Halma brings substantial human and financial resources to the table, while offering the ability to provide customers not only Accudynamics products, but a wide range of fluid technology solutions.”
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE